Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03467373
Title A Study of RO7082859 in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Non-Hodgkin Lymphomas
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications

non-Hodgkin lymphoma

diffuse large B-cell lymphoma

Therapies

Tocilizumab

Cyclophosphamide + Doxorubicin + Obinutuzumab + Prednisone + Vincristine Sulfate

Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate

RO7082859

Cyclophosphamide + Doxorubicin + Obinutuzumab + Prednisone + RO7082859 + Vincristine Sulfate

Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + RO7082859 + Vincristine Sulfate

Age Groups: senior | adult
Covered Countries USA | ITA | FRA | ESP | DEU | CAN


No variant requirements are available.